After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...